Daratumumab-Based Second Line Therapy Improves Outcomes After VRD Induction, Upfront Autologous Transplant, and Lenalidomide Maintenance.
- DOI
- 10.1016/j.clml.2026.02.014
- Published
- 2026 May
- Container
- Clinical lymphoma, myeloma & leukemia
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.clml.2026.02.014,
title = {Daratumumab-Based Second Line Therapy Improves Outcomes After VRD Induction, Upfront Autologous Transplant, and Lenalidomide Maintenance.},
author = {Pasvolsky O and Marcoux C and Milton DR and Tanner MR and Bashir Q and Srour S and Saini N and Lin P and Siddiqui UR and Khan HN and Haider AA and Ramdial J and Nieto Y and Tang G and Lakhani K and Aljawai Y and Kebriaei P and Lee HC and Patel KK and Thomas SK and Orlowski RZ and Champlin RE and Shpall EJ and Qazilbash MH},
year = {2026},
journal = {Clinical lymphoma, myeloma \& leukemia},
doi = {10.1016/j.clml.2026.02.014},
url = {https://doi.org/10.1016/j.clml.2026.02.014}
}RIS
TY - JOUR TI - Daratumumab-Based Second Line Therapy Improves Outcomes After VRD Induction, Upfront Autologous Transplant, and Lenalidomide Maintenance. AU - Pasvolsky O AU - Marcoux C AU - Milton DR AU - Tanner MR AU - Bashir Q AU - Srour S AU - Saini N AU - Lin P AU - Siddiqui UR AU - Khan HN AU - Haider AA AU - Ramdial J AU - Nieto Y AU - Tang G AU - Lakhani K AU - Aljawai Y AU - Kebriaei P AU - Lee HC AU - Patel KK AU - Thomas SK AU - Orlowski RZ AU - Champlin RE AU - Shpall EJ AU - Qazilbash MH PY - 2026 JO - Clinical lymphoma, myeloma & leukemia DO - 10.1016/j.clml.2026.02.014 UR - https://doi.org/10.1016/j.clml.2026.02.014 ER -
APA
O, P., C, M., DR, M., MR, T., Q, B., S, S., N, S., P, L., UR, S., HN, K., AA, H., J, R., Y, N., G, T., K, L., Y, A., P, K., HC, L., KK, P., SK, T., RZ, O., RE, C., EJ, S., & MH, Q. (2026). Daratumumab-Based Second Line Therapy Improves Outcomes After VRD Induction, Upfront Autologous Transplant, and Lenalidomide Maintenance.. Clinical lymphoma, myeloma & leukemia. https://doi.org/10.1016/j.clml.2026.02.014
Source records
- pubmed · retrieved 2026-09-26T04:11:44.510Z